MRC1 and neoplasm: Notably, there was a reduction of F4/80+ tumor-associated macrophages (TAM) and especially in F4/80+ CD206+ cells in tumors from IL17A−/− mice and with a greater extent in tumors from WT mice treated with the anti-IL17A mAb (Figure 6a).